SS-31 Peptide Study: New Hope for Ulcerative Colitis

Ulcerative colitis (UC) affects millions of people worldwide, causing chronic inflammation, intestinal damage, and a significantly diminished quality of life. Despite existing therapies, many patients continue to experience inadequate symptom control and long-term complications. Now, a compelling preclinical study published in the Journal of Gastroenterology and Hepatology (Mei et al., 2026) suggests that a novel nanoparticle platform incorporating the mitochondria-targeting SS-31 peptide may offer a new avenue for treating UC — one that works at the cellular and subcellular level to address the root drivers of intestinal inflammation.

What This Study Found

Researchers developed an innovative drug delivery system called KSF@SS31@S100Ns — a mouthful of a name that reflects its multi-layered design. At its core, the nanoparticle carries kaempferol, a naturally derived flavonoid with known anti-inflammatory properties, encapsulated within silk fibroin (SF) nanoparticles. These nanoparticles were then conjugated with SS-31, a mitochondria-targeting peptide, and coated with a pH-sensitive polymer called Eudragit S100 to ensure the payload survives the acidic environment of the stomach and reaches the colon intact.

The research team's central hypothesis was that mitochondrial dysfunction in macrophages is a key driver of the chronic, unresolved inflammation seen in UC. When macrophages — immune cells that patrol the gut lining — suffer mitochondrial damage, they shift toward a pro-inflammatory state known as the M1 phenotype, releasing cytokines that perpetuate tissue injury. The study sought to reverse this process.

In laboratory experiments using LPS-stimulated macrophage cells (RAW264.7), researchers found that the SS-31-conjugated nanoparticles demonstrated enhanced uptake into macrophages and superior localization within mitochondria compared to control formulations. The treatment was associated with:

• Restored mitochondrial membrane potential and increased ATP production
• Reduced reactive oxygen species (ROS), a hallmark of oxidative stress
• Promoted mitophagy — the cellular process of clearing damaged mitochondria
• A measurable shift in macrophages from the pro-inflammatory M1 phenotype toward the anti-inflammatory M2 phenotype

The researchers found these effects appeared to be mediated through activation of the SIRT3/FOXO3a signaling pathway, a molecular axis known to regulate mitochondrial homeostasis and oxidative stress responses.

In a mouse model of colitis induced by dextran sulfate sodium (DSS), oral administration of the nanoparticles led to accumulation in inflamed colon tissue. The study reports that treated animals showed reduced disease severity, suppressed levels of pro-inflammatory cytokines, elevated interleukin-10 (IL-10, an anti-inflammatory mediator), restoration of tight-junction proteins critical to intestinal barrier integrity, and increased proportions of M2 macrophages in colonic tissue.

It is important to emphasize that this study was conducted in cell cultures and an animal model. Human clinical trials have not yet been conducted, and these findings cannot be directly applied to human patients at this time.

Clinical Significance

What makes this research particularly noteworthy is not just its results, but the mechanistic strategy it represents. Rather than broadly suppressing the immune system — the approach taken by many current UC therapies — this nanoplatform attempts to reprogram immune cell behavior by restoring cellular energy metabolism.

The SS-31 peptide plays a central role in this strategy. SS-31 (also known as elamipretide) is a mitochondria-targeting tetrapeptide that has been studied in various contexts for its ability to stabilize the inner mitochondrial membrane, reduce oxidative stress, and improve mitochondrial function. Its inclusion in this nanoparticle system appears to be what enables the therapeutic cargo to reach and act within the mitochondria of inflamed macrophages.

The colon-targeting design addresses one of the fundamental challenges in treating inflammatory bowel diseases: getting therapeutic agents to the site of inflammation in sufficient concentrations while minimizing systemic side effects. The pH-sensitive Eudragit S100 coating is specifically designed to dissolve only at the higher pH levels found in the lower gastrointestinal tract, suggesting a degree of site-specificity that could be clinically meaningful if the approach translates to humans.

The study also highlights the SIRT3/FOXO3a pathway as a potentially underexplored therapeutic target in UC. SIRT3 is a mitochondrial deacetylase that regulates oxidative stress responses, and its activation appears to promote the anti-inflammatory reprogramming of macrophages observed in this research. This adds to a growing body of evidence suggesting that mitochondrial biology may be deeply intertwined with intestinal immune regulation.

Current Access and Compliance Context

The nanoparticle system described in this study is a preclinical investigational platform and is not currently available as a treatment for ulcerative colitis or any other condition. It has not been evaluated in human clinical trials, reviewed by regulatory agencies such as the FDA, or approved for therapeutic use.

The SS-31 peptide component, however, has been the subject of broader clinical investigation in other disease contexts, including heart failure and mitochondrial myopathy, demonstrating that mitochondria-targeting peptides are an active and legitimate area of translational medical research. Kaempferol, the flavonoid payload used in this system, is also a well-characterized compound with a substantial body of preclinical research supporting its anti-inflammatory properties.

Patients currently managing ulcerative colitis should continue to work closely with their gastroenterologist and follow established treatment protocols, which may include aminosalicylates, corticosteroids, immunomodulators, and biologic therapies. Research such as this study represents the pipeline of future possibilities, not current clinical options.

What Patients Should Know

If you or someone you love is living with ulcerative colitis, studies like this one offer a reason for cautious optimism. The science of peptide-based therapeutics is advancing rapidly, and researchers are increasingly looking beyond broad immunosuppression toward more targeted, mechanism-driven approaches.

Here are several key takeaways from this research:

• Mitochondrial health matters in gut inflammation. The study suggests that damaged mitochondria in immune cells may actively fuel the chronic inflammation seen in UC, pointing to a cellular target that has historically received less attention in gastroenterology.
• Peptides can be engineered for precision delivery. The use of SS-31 to direct therapeutic cargo specifically to mitochondria within macrophages illustrates how peptide science is enabling increasingly sophisticated drug delivery strategies.
• Human data is needed. As with all preclinical research, the findings in cell lines and mouse models must be validated in human clinical trials before any conclusions about safety or efficacy in people can be drawn.
• Stay informed. Connecting with a physician who is knowledgeable about emerging peptide research and integrative approaches to inflammatory conditions can help you understand how evolving science may eventually apply to your care.

Conclusion

The research by Mei and colleagues represents a meaningful step forward in the science of peptide-mediated, mitochondria-targeted therapy for inflammatory bowel disease. By engineering a nanoparticle system that leverages the SS-31 peptide to restore mitochondrial function and repolarize macrophages in the inflamed colon, the study suggests a new mechanistic pathway through which UC might one day be addressed at its cellular roots. While human clinical validation remains an essential next step, this work adds important evidence to the growing case for mitochondria-targeting peptides as a promising frontier in gastrointestinal medicine.

To find a physician experienced in peptide therapies and emerging research-based treatments, visit peptideassociation.org/find-a-doctor.

---

Medical Disclaimer: This article is intended for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. The research discussed reflects preclinical findings in cell cultures and animal models; human efficacy and safety have not been established. Always consult a qualified healthcare professional before making any decisions about your health or treatment options.

---

Citation: Mei R, Zhang R, Li Z, et al. Oral Colon- and Mitochondria-Targeted Nanoparticles Alleviate Ulcerative Colitis by Reeducating Macrophage Polarization via SIRT3/FOXO3a-Mediated Mitochondrial Restoration. Journal of Gastroenterology and Hepatology. 2026. doi:10.1111/jgh.70668. PMID: 42638278.